PhRMA Code on Interactions with Healthcare Professionals Signatory Companies

In June 2008, the PhRMA Board of Directors unanimously adopted measures to enhance the PhRMA Code on Interactions with Healthcare Professionals. The revised, voluntary Code, which took effect January 1, 2009, reaffirms that interactions between pharmaceutical company representatives and healthcare professionals should be focused on informing the healthcare professionals about products, providing scientific and educational information, and supporting medical research and education.

Among its changes, the revised Code provides that all companies that interact with healthcare professionals about pharmaceuticals should adopt procedures to assure adherence to the Code. It also states that PhRMA will identify on its website all companies that announce their commitment to abide by the Code and complete (at the appropriate time) an annual certification that they have policies and procedures in place to foster compliance with the Code.

The following is a list of all signatory companies that have announced that they intend to abide by the Code:

AbbVie Inc.

Allergan, Inc.

Amgen Inc.

Anacor Pharmaceuticals, Inc.

Astellas US, LLC

AstraZeneca LP

Bayer Corporation

Biogen

Boehringer Ingelheim Pharmaceuticals, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

Cell Therapeutics, Inc.

Corcept Therapeutics. Inc.

Cumberland Pharmaceuticals Inc.

Daiichi Sankyo, Inc.

Eisai Inc.

EMD Serono, Inc.

Endo Pharmaceuticals Inc.

Exelixis. Inc.

Genentech. Inc.

Genzyme Corporation, A Sanofi Company

GlaxoSmithKline

Grifols, Inc.

Horizon Pharma

Jazz Pharmaceuticals, Inc.

Johnson & Johnson

(Pharmaceutical Companies)

LEO Pharma Inc.

Eli Lilly and Company

Lundbeck LLC

Mallinckrodt Pharmaceuticals

Marathon Pharmaceuticals, LLC

Medivation, Inc.

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Noven Pharmaceuticals, Inc.

Novo Nordisk, Inc.

Otsuka America Pharmaceutical, Inc. (OAPI)

Otsuka Pharmaceutical Development &

Commercialization, Inc. (OPDC)

Pfizer Inc

Purdue Pharma L.P.

Regeneron Pharmaceuticals, Inc.

Sanofi

Sentynl Therapeutics, Inc.

Shionogi Inc.

Sigma-Tau Pharmaceuticals, Inc.

Sucampo

Sunovion Pharmaceuticals Inc.

Takeda Pharmaceuticals U.S.A., Inc.

Theravance, Inc.

UCB, Inc.

XenoPort, Inc.

Zogenix, Inc.